The QualityStocks Daily Wednesday, September 26th, 2018

Today's Top 3 StockMarketWatch

MarketClub Analysis (ONTX) +1,355.20%

StockMarketWatch (ANY) +51.62%

QualityStocks (INQD) +37.50%

The QualityStocks Daily Stock List

Noble Roman's, Inc. (NROM)

Wall Street Resources, TaglichBrothers,, FeedBlitz, The Bowser Report, StockOodles, and SmallCapVoice reported on Noble Roman's, Inc. (NROM), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.

Noble Roman's, Inc. sells and services franchises and licenses for non-traditional foodservice operations and stand-alone take-n-bake locations. Its business model comprises three growth venues. These are Grocery Take-n-Bake Licensing; Non-Traditional Franchising; and Stand-Alone Franchising. It franchises and licenses under the Noble Roman’s Pizza, Noble Roman’s Take-N-Bake, Tuscano’s Italian Style Subs, and Noble Roman's Craft Pizza & Pub (CPP) trade names. Noble Roman’s is based in Indianapolis, Indiana.

Noble Roman’s has awarded franchise and/or license agreements in all 50 U.S. States plus Washington, D.C. Moreover, it has awarded franchise and/or license agreements in Canada, Puerto Rico, the Bahamas, Italy, and the Dominican Republic.

The Company’s Craft Pizza & Pub (CPP) features two styles of hand-crafted, made-from-scratch pizzas with a selection of 40 different toppings, cheeses, and sauces. Additionally, beer and wine are featured, with 16 different beers on tap.

Concerning Non-Traditional Venues, these are typically located in a host facility whose primary business is other than foodservice. These facilities can add pizza-focused foodservice as a Revenue Center; as a Facility Draw; and as an Employee Benefit.

Regarding Stand-Alone Venues, these are traditional pizzeria locations and Take-n-Bake locations. There is a merging over time between the kinds of Stand-Alone Venues: Live Yeast Dough; Hand-Rolled Breadsticks; and Baking Services.

Grocery Take-n-Bake Licensing involves licensing to sell Noble Roman’s Pizza. This is a component program using Noble Roman’s ingredients, in which delis assemble pizzas from standard Noble Roman’s ingredients.

The first Noble Roman's CPP opened on January 31, 2017 in Westfield, Indiana in the Monon Marketplace on Main Street/Highway 32 across from Grand Park.
On April 18, 2018, Noble Roman's announced that its Westfield, Indiana location had record sales for the most recent week and also the single highest sales day for the nearly 15 months it has been open.

Mr. Scott Mobley, Noble Roman's President and Chief Executive Officer, said, ''We are extremely encouraged with the continued development of our Westfield, Indiana Craft Pizza & Pub location. As the first to pass its one-year anniversary mark, setting new sales records is a great achievement. We believe this demonstrates the strength of the concept overall, and we are proud of the management team and employees in place as we celebrate their accomplishment.”

During Q1 2018, Noble Roman's signed a lease for its fourth company-operated Craft Pizza & Pub location in Carmel, Indiana. The expectation is that it will open to the public on May 29, 2018. The three current Craft Pizza & Pub locations all continue to surpass Management's pre-opening sales expectations.

During Q1 2018, Noble Roman’s refocused its efforts on selling franchises for non-traditional franchised locations. The Company has sold 18 such franchises between January 1, 2018 and May 12, 2018.

Noble Roman's, Inc. (NROM), closed Wednesday's trading session at $0.64, up 5.79%, on 57,500 volume with 16 trades. The average volume for the last 3 months is 27,365 and the stock's 52-week low/high is $0.50/$0.87.


United Cannabis Corp. (CNAB)

Center Alert,, StreetAuthority Daily, Actual Gains, Broad Street, TopPennyStockMovers, StocksImpossible, Cannabis Financial Network News, PricelessPennyStocks, Stockgoodies, Promotion Stock Secrets, Wealth Insider Alert, Wall Street Mover, Market Intelligence, Money Map Press, MyBestStockAlerts, and Wall Street Wolves reported previously on United Cannabis Corp. (CNAB), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

United Cannabis Corp.’s dedication is to the development of phyto-therapeutic based products supported by patented technologies for the pharmaceutical, medical, and industrial markets. The Company formed to provide leadership in the medical cannabis industry. This is through providing patient driven solutions intent on improving biomedical and pharmaceutical pursuits using cannabis-based research, products, and services. United Cannabis is based in Denver, Colorado.

A biotechnology enterprise, United Cannabis is the creator of Prana Bio Nutrient Medicinals. The Company’s A.C.T. Now Program and Prana Bio Nutrient Medicinals provide a complete solution designed to allow physicians and patients to implement and monitor effective therapy protocols.

Prana Bio Nutrient Medicinals is a complete, full spectrum cannabinoid system. It uses the whole cannabis plant through controlling specific cannabinoid ratios, accurate dosing, and numerous non-abrasive delivery methods.

The A.C.T. Now program provides nutritional recommendations to help patients suffering from chronic pain, opiate dependency, inflammation, glaucoma, PTSD, neuropathy, multiple sclerosis, fibromyalgia, Crohn’s, IBS, seizures, epilepsy, paralysis, autoimmune, autism, tumors, HIV/AIDS, and many kinds of cancer.

United Cannabis provides consulting services, proprietary products, and licenses its intellectual property (IP) to businesses in the cannabis industry. The Company owns distinct IP relating to the legalized growth, production, manufacture, marketing, management, use and distribution of medical and recreational marijuana and marijuana infused products. It has established affiliate relationships with Harborside Health Center of California, Prana Bio Nutrient Medicinals, Bubbleman, Blue River, and Cannabinoid Research & Development (CRD).

United Cannabis has a majority share of Prana Therapeutics, Inc. (PTI). PTI is a clinical stage biotechnology company developing Polymolecular Botanical therapeutics for the oncology, neurology, as well as orthopaedic markets. Prana concentrates on developing targeted therapeutics for the prevention of the negative side effects of chemotherapy, management of rheumatoid arthritis, and treatment of brain cancer.

In February, United Cannabis announced that it started extraction services at its Colorado industrial hemp processing plant. The Company established the Facility to provide contract manufacturing to farmers working under the 2014 Federal Farm Bill and Colorado's Department of Agriculture's Industrial Hemp Program. The multi-function Facility includes extraction, purification, testing and processing equipment, and also packaging, fulfillment, and secure storage capabilities.

Recently, United Cannabis announced that Jamaica's University of the West Indies' Ethics Committee reviewed and approved its proposal to conduct clinical trials on its Prana Bio Nutrient Medicinals P1 Capsules for the treatment of chronic pain.

The study, titled, "An Open-Label, Phase 1, 2-Way crossover study evaluating the pharmacokinetics of Prana P1 THC activated capsules," will be conducted in association with Cannabinoid Research & Development (CR), United Cannabis’ Jamaican subsidiary, at the Centre For Cannabis Research at the University Of West Indies, Mona Campus, in Jamaica.

Last month, United Cannabis announced that Mr. Jesús M. Vázquez joined the Company as Vice President and General Counsel. Mr. Vázquez will be responsible for supervising management of United Cannabis’ IP assets. He specializes in IP related matters, with an increasing emphasis in the Cannabis sector.

United Cannabis Corp. (CNAB), closed Wednesday's trading session at $0.59, up 0.68%, on 218,542 volume with 185 trades. The average volume for the last 3 months is 538,273 and the stock's 52-week low/high is $0.41/$2.50.


Airborne Wireless Network (ABWN)

Epic Stock Picks,, Penny Stock 101, StockRockandRoll, Penny Stock Craze, Penny Stocks Finder, OTCBB Journal, Stock Commander, Profitable Trader Authority, Damn Good Penny Picks, Penny Picks, Beacon Equity Research, Broad Street, and SuperStockTips reported earlier on Airborne Wireless Network (ABWN), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Airborne Wireless Network’s mission is to be a high-speed broadband internet pipeline to improve coverage connectivity now lacking. Its intention is to create a high-speed broadband airborne wireless network through linking commercial aircraft in flight. Each aircraft participating in the network will act as an airborne repeater or router, sending and receiving broadband signals from one aircraft to the next. This will create a digital superhighway in the sky. Airborne Wireless Network has its head office in Simi Valley, California.

Airborne Wireless Network has completed its acquisition of Patent Number US 6,285,878 B1 and the Trademark "Infinitus Super Highway". These acquired assets serve as a blueprint and road map for it to develop its "Airborne Wireless Network”.

Concerning its Wholesale Carrier Network, the Company’s plan is to use commercial aircraft as “mini-satellites”. Its primary target customer-base will be international data and communications service providers. Airborne Wireless Network’s system is to operate in a safe and controlled environment, usually between 20,000 and 40,000 feet (6,000-12,000 m).

The Company is developing a completely meshed network. In a completely meshed network, signals come in from numerous directions. The system will route signals around any obstructions. Fundamentally, it is a virtual airborne Worldwide Web. Because it is a meshed network, it is comparable to a web where all nodes are connected through many links.

Airborne Wireless Network will act as a wholesale carrier with target customers. The Company believes that its network, upon development, should provide low cost, high-speed connectivity to rural areas, island nations, ships at sea, oil platforms, in addition to connectivity to commercial and private aircraft in flight.

In January of this year, Airborne Wireless Network announced that on December 26, 2017, it entered into a service agreement with iNTELLICOM Technologies, Inc. to support the development and advancement of its Infinitus Super Highway™.

This past March, Airborne Wireless Network announced that on March 6, 2018 it entered into an Agreement with South Bay Aviation (Torrance, California based), for two airplanes for the upcoming second flight test of the Infinitus Super Highway network. The Company looks to expand on its initial RF proof of concept test that was completed in May 2017 using two Boeing 767-300ER aircraft and a mobile mast imitating a ground station.

Also in March, Airborne Wireless Network announced that on March 26, 2018 it applied with the FAA (Federal Aviation Administration) for experimental operating certificates for each flight test demonstration aircraft. Upon approval, these applications will allow for the modification and installation of the Infinitus Superhighway RF and Optical components on each of the two Cessna aircraft Airborne Wireless Network has arranged for use in connection with its upcoming demonstration tests of Infinitus.

Airborne Wireless Network (ABWN), closed Wednesday's trading session at $0.0022, up 29.41%, on 14,650,000 volume with 214 trades. The average volume for the last 3 months is 372,430,673 and the stock's 52-week low/high is $0.0016/$93,600.00.


American Green, Inc. (ERBB)

InvestorsHub and reported on American Green, Inc. (ERBB), and today we report on the Company, here at the QualityStocks Daily Newsletter.

American Green, Inc. operates as a technology company in the medical cannabis industry in the United States. It became one of the first publicly traded technology companies in the medical cannabis industry worldwide, beginning in 2009, with the introduction of the ZaZZZ machine for automated, age-verifying dispensing of cannabis-based medicines. The Company’s commitment is to the developing cannabis market. American Green is headquartered in Phoenix, Arizona.

American Green has a state-of-the-art cultivation facility in Phoenix, Arizona. In addition, the Company has involvement with the sale or creation of several apps supporting cannabis and small businesses alike. This includes the Blaze Now dispensary locator, which can be found in the Apple and Android app stores and the Company’s own Xpress app.

American Green has its AGM verified vending system. The Company enables businesses to securely vend age-restricted products. This includes cannabis, beer, tobacco, pharmaceuticals, and more.

American Green purchased the desert town of Nipton, California in September of 2017. In October, it announced that it completed Phase One of its integration into Nipton. American Green has plans ready for presentation to the corresponding regulatory entities to facilitate and accomplish its stated goals for the town's future -- becoming the first energy-independent cannabis-friendly town in the U.S.

The new focus for the Town of Nipton is as a host location for cannabis tourism and a hub for art and nature educational workshops. The town’s traditional role involved mining, ranching, and also railroading.

Recently, American Green announced that it entered into a Joint Venture (JV) to create a CBD processing plant in Nipton, California with MediaTechnics Corporation (MEDT).

With this JV, MEDT is to specify, procure, design, develop and install a state-of-the-art extraction facility in Nipton that can extract Cannabidiol (CBD) from Industrial Hemp.

Industrial hemp contains less than 0.003 percent THC, below the level where it can be considered a psychoactive drug. Along with American GreenCrete, these facilities are among the first of numerous other revenue-generating opportunities American Green plans for Nipton and the surrounding areas. This includes Searchlight and Primm Nevada.

In April, American Green announced that it completed its acquisition of Delta International Oil and Gas (DLTZ) via the sale of its Nipton assets. Therefore, American Green has gained control of Delta.

Delta will be operated as a subsidiary of American Green. American Green will consolidate Delta’s financials with its own. The expectation is that American Green’s new subsidiary, Delta International, will invest heavily in Nipton and other American Green-run projects.

Delta’s intention is to register up to $5,000,000 of non-voting preferred stock on Form S-1 so as to fund future development in Nipton, and other projects. This includes, first and foremost, the consolidation of any properties, mostly already under contract, of any real value in the Ivanpah Valley in which Nipton is located.

Moreover, in April, American Green and Delta International Oil and Gas announced that they are planning to form a new Political Action Committee and build a new Research and Education Institute in Nipton, California.

American Green, Inc. (ERBB), closed Wednesday's trading session at $0.0008, up 14.29%, on 44,635,377 volume with 157 trades. The average volume for the last 3 months is 65,313,368 and the stock's 52-week low/high is $0.0007/$0.0023.


Identillect Technologies Corp. (IDTLF)

Stockhouse, Investopedia, OTC Markets, InvestorsHub, Investors Hangout, and Stock Orange reported on Identillect Technologies Corp. (IDTLF), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Identillect Technologies Corp. is a foremost provider of SaaS (Software as a Service) email security. The Company’s Delivery Trust™ email security technology platform enables individuals and businesses of all sizes a cost-effective way to create a more secure digital environment and protect against cyber security risks. Identillect Technologies has its head office in Irvine, California. The Company is a trusted leading provider of HIPAA (Health Insurance Portability and Accountability Act) compliant email security.

Delivery Trust™ is the industry’s simplest plug and play security solution. It is an award -winning, multi-platform plug-in. It gives users complete control of their emails, for one low price.

Delivery Trust™ is available for iPhone®, iPad®, Android, Windows, and Mac PC's and Laptops and the web's most popular email platforms. Delivery Trust™ has an extensive range of features. These include state-of-the-art encryption technology, restricting email forwarding and printing, receipt confirmation, limiting time available to view, and retracting sent emails.

Identillect Technologies has a service collaboration with the National Association of Professional Agents (NAPA), providing NAPA members access to the Company's set of compliance tools. This includes the Identillect Delivery Trust™ email encryption service. NAPA specializes in building custom company-sponsored E&O and benefit programs tailored to meet the unique requirements of a sponsoring company’s distribution force.

Last month, Identillect Technologies announced that SF Perio & Implants chose Delivery Trust® to secure its email communications containing sensitive protected health information (PHI). SF Perio provides world-class care in periodontal (gum) disease, oral surgery, as well as dental implants. SF Perio centers on providing the latest procedures for treating periodontal disease and placing dental implants tailored to their client’s needs.

Identillect Technologies is experiencing continued success in providing secure communication to its partners. Smile Savvy, Inc. chose Delivery Trust® to secure email communications of the pediatric dental practices supported nationally and internationally and the client response has been favorable.

Mr. Todd Sexton, Identillect Technologies’ Chief Executive Officer, said, “Identillect has engaged in a campaign to educate and provide secure communication for all Smile Savvy members. This campaign has already seen early success with almost 40 percent of the clients viewing Delivery Trust choosing to implement the service. We are noticing an increasing rate of interest and adoption with ongoing campaigns to Smile Savvy clients. Positive growth with Smile Savvy and other similar partnerships is projected throughout 2018.”

Identillect Technologies Corp. (IDTLF), closed Wednesday's trading session at $0.052, up 10.87%, on 78,500 volume with 7 trades. The average volume for the last 3 months is 34,067 and the stock's 52-week low/high is $0.0404/$0.4763.


Leafbuyer Technologies, Inc. (LBUY)

Barchart, Insider Financial, and OTC Markets reported on Leafbuyer Technologies, Inc. (LBUY), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

Leafbuyer Technologies, Inc. is a top cannabis technology platform. Leafbuyer is one of the most wide-ranging online sources for searchable cannabis deals, specials, and also menu’s. Leafbuyer is the official marijuana deals platform of Voice Media Group, Grasscity, Dope Media and LA Weekly. Formed in 2012, Leafbuyer Technologies has its headquarters in Greenwood Village, Colorado.

Leafbuyer’s online network reaches millions of marijuana consumers each month. Leafbuyer Technologies continues to expand into every legal state. The Company is working to be the ultimate cannabis resource, providing consumers and businesses with the resources they require to thrive in the cannabis industry. connects consumers with dispensaries. The Company works alongside businesses to highlight their unique products and build a network of loyal patrons.

Leafbuyer Technologies announced last year that it entered into expansion agreements with two major dispensary chains. These are Sweet Leaf Marijuana Centers and Green Dragon Cannabis Co.

Leafbuyer Technologies is strategically positioned for considerable expansion into the California Recreational cannabis market this year. With the passage of Proposition 64, effective January 1, 2018, California residents no longer need doctor’s approval to purchase cannabis. Leafbuyer says the Company is well-prepared to connect consumers with dispensaries across California.

This past March, Leafbuyer Technologies announced that Phase Two of its advanced large-scale platform based on blockchain technology has started. Working with its select specialists, Wunderkind Technologies, LLC, the second strategic phase has started to reliably verify transactions with dispensaries. Blockchain will allow Leafbuyer Technologies’ systems management team to accurately, in real time, verify referrals, customer traffic, point-of-purchase, pricing and a broad number of proprietary data points for Leafbuyer’s clients.

Moreover, last month, Leafbuyer Technologies announced its new partnership with DOPE Media. The new partnership will expand the reach of Leafbuyer's deals platform to millions of new cannabis users throughout North America. DOPE Media is a highly-respected media veteran in the legal cannabis industry.

Leafbuyer Technologies has launched Leafbuyer TV. This is the new television arm of the Company. Leafbuyer TV will include television news style segments to complement and enhance the News and Blog section of its website, and also Leafbuyer’s social media platforms. This new TV service will be free to the public.

Leafbuyer Technologies, Inc. (LBUY), closed Wednesday's trading session at $1.04, up 20.93%, on 632,640 volume with 590 trades. The average volume for the last 3 months is 196,384 and the stock's 52-week low/high is $0.55/$3.15.


Centenera Mining Corporation (CTMIF)

Investing News, Stockhouse, MarketWatch, Streetwise Reports, 4-Traders, Junior Mining Network, WalletInvestor, Investor Place, The Subway Trader, Gold Stock Data, and The Wolf Trader reported on Centenera Mining Corporation (CTMIF), and today we choose to highlight the Company, here at the QualityStocks Daily Newsletter.

A mineral resource company, Centenera Mining Corporation concentrates 100 percent on mineral resource assets in Argentina. Its intention is to focus its 2018 exploration activities on drill-testing its flagship Esperanza copper-gold project.

Centenera Mining has a diversified portfolio of assets in Argentina. The Company’s Executive Team has exploration, development, as well as financing experience in South America. Centenera Mining is headquartered in Vancouver, British Columbia.

The Company’s other assets include the El Quemado lithium pegmatite project in Salta Province and the Organullo gold project. The Organullo project has roughly 8,000 meters of historical drilling and assay results. 

Organullo has a geological target range from 19.8 million tonnes grading at 0.94 g/t gold (600,000 ounces) to 31.6 million tonnes grading 0.92 g/t gold (940,000 ounces) using a 0.5 g/t gold cut-off-grade. However, insufficient exploration and geological modeling has taken place to define a mineral resource. The Company notes that it is uncertain if further exploration will result in the delineation of a mineral resource.

Moreover, Centenera Mining’s project pipeline includes the Crosby Project, the El Penon Project, the above-mentioned El Quemado project, the Mina Angela Project, and the Trigal Project.

Centenera Mining acquired Esperanza in 2017. The Company has an option to earn 100 percent interest for cash payments of US$2.3M over 6 years and the issuance of US$0.5M CT stock. The Esperanza Project is subject to a 2 percent Net Smelter Return (NSR) (right to buy 0.5 percent for US$1M cash).

The flagship Esperanza Cu-Au Project in San Juan Province has existing infrastructure nearby. The Project has a Copper-Gold Porphyry System. Mineralization is open in all directions.

The 2018 drill program is testing bulk tonnage potential. The aim is to drill, add value, and advance to joint venture (JV) or sale.

Yesterday, Centenera Mining announced it received the final batch of drill results from drill hole 18-ESP-025 at the Esperanza Copper-Gold Porphyry project.  Drill hole 18-ESP-025 collared in mineralization and continued to drill mineralized rock to end of hole (387m; hole abandoned because of drilling difficulties).  Mineralization remains open at depth.

Laboratory results were returned for the entire drill hole grading 0.57 percent copper and 0.27g/t gold; 0.78 percent copper equivalent.  This includes 232m from surface grading 0.74 percent copper and 0.33g/t gold; 1.00 percent copper equivalent.

Centenera Mining Corporation (CTMIF), closed Wednesday's trading session at $0.0566, up 12.97%, on 3,000 volume with 2 trades. The average volume for the last 3 months is 5,140 and the stock's 52-week low/high is $0.008/$0.205.


Northsight Capital, Inc. (NCAP)

AwesomePennyStocks, Equity Clock, Marketwired, Investors Hub, MarketWatch, Barchart, The Street,, OTC Markets, Insider Monkey, Stockopedia,, and WhaleWisdom reported on Northsight Capital, Inc. (NCAP), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Northsight Capital, Inc. consists of a portfolio of online Cannabis-related websites that are undergoing development and operated by the Company. These sites incorporate manifold facets of the Cannabis industry. The Company is presently transitioning into two sectors. One is the Bitcoin ATM service industry. The other is its contemporary cannabis advertising and media platform. Northsight Capital is based in Scottsdale, Arizona.

Northsight Capital does not sell or distribute any cannabis products. The Company is looking to acquire digital or publishing companies in the space.

Northsight Capital has its This portal provides consumers with a geo-targeted map directory of medical and recreational dispensaries, head shops, doctors, attorneys and more within the Cannabis industry. Weed Depot has an entire platform of content suited for every facet of advertising and marketing to consumers from all businesses in the cannabis industry.

Northsight also has its This is a foremost job site in the Cannabis space. has 2,000 to 3,000 visitors each day. It has about 1 million page views each month.

Northsight Capital announced in November of 2017 that it signed a preliminary agreement to acquire 80 percent of Westcliff Technologies. Currently, Westcliff operates a digital asset retail brokerage as “National Bitcoin ATM”. In addition, it provides consumers the ability to purchase Bitcoin immediately through a network of kiosks (ATM’s) located in the United States.

Northsight Capital earlier completed its acquisition of Crush Mobile, LLC. Crush Mobile has developed a group of dating sites with a presence in the Latino, Israeli, and African American communities.

Crush Mobile is now a part of Northsight Capital’s growing media group. Also, Crush Mobile will be incorporating into its dating applications suite Northsight Capital's "Joint Lovers" dating app, which will focus on the Cannabis space.

At the end of January 2018, Northsight Capital announced that it signed a non-binding Letter of Intent (LOI) to acquire Uptick Newswire, Inc. Uptick Newswire is one of the top outlets for micro-cap companies to display their company's current and future potential.

In February, Northsight Capital, following completion of its acquisition of Crush Mobile, LLC, announced it engaged Sonya Kreizman and Yossi Shemesh, former Crush Mobile management, as consultants. The two will join Northsight Capital to manage the Crush Mobile Apps and build and launch the new Joint Lovers dating app.

Ms. Sonya Kreizman is Co-Founder of Crush Mobile. She has a wide-ranging background in brand consulting and marketing. Ms. Kreizman co-founded Jspace, which is a leading Jewish culture website.

Yossi Shemesh is a Senior Product and Engineering Lead. He is Co-Founder of two successful consumer and B2B facing ventures. Mr. Shemesh was Co-Founder of Mobli, a photo and video sharing platform.

Northsight Capital, Inc. (NCAP), closed Wednesday's trading session at $0.009, up 2.11%, on 289,978 volume with 10 trades. The average volume for the last 3 months is 318,181 and the stock's 52-week low/high is $0.006/$0.14.


Wize Pharma, Inc. (WIZP)

Stockopedia, 4-Traders, Stockhouse, InvestorsHub, OTC Markets, Barchart, MarketWatch, Stockwatch, InsiderMole, and CapitalCube reported on Wize Pharma, Inc. (WIZP), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

A clinical-stage biopharmaceutical company, Wize Pharma, Inc. concentrates on the treatment of ophthalmic disorders. This includes dry eye syndrome (DES). The Company was previously known as Star Night Technologies Ltd. It changed its corporate name to Wize Pharma, Inc. in July of 2015. The Company is based in Hod Hasharon, Israel. Wize Pharma lists on the OTC Markets’ OTCQB.

Wize Pharma has in-licensed certain rights to purchase, market, sell and distribute a formula called LO2A, a drug developed for the treatment of DES, and other ophthalmological illnesses, including conjunctivochalasis (CCH) and Sjögren's Syndrome.

At present, LO2A is registered and marketed by its inventor in Germany and Switzerland for the treatment of DES, in Hungary for the treatment of DES and CCH, and in the Netherlands for the treatment of DES and Sjögren's Syndrome.

Wize Pharma is now conducting a Phase II trial of LO2A for patients with CCH and a Phase IV study for LO2A for DES in patients with Sjögren's.

In late March, Wize Pharma announced that it enrolled the first patient in its Phase IV clinical trial in Israel for LO2A in the symptomatic treatment of dry eye syndrome (DES) in patients with Sjögren's syndrome. The randomized, double-masked study will evaluate LO2A versus Alcon's Systane® Ultra UD, an over-the-counter (OTC) lubricant eye drop product used to relieve dry and irritated eyes.

The design of this study (in addition to meeting marketing approval requirements in Israel) is to support the Company’s clinical approval pathway for LO2A for the treatment of DES in patients with Sjögren's in other markets including the United States, China, and Ukraine. LO2A is already approved in Israel for the treatment of DES. The expectation is that sales will start in Israel this year.

Recently, Wize Pharma announced that it completed enrolment of all 62 patients in its multi-center Phase II clinical trial in Israel of LO2A for the treatment of patients with moderate to severe Conjunctivochalasis (CCH). The present Phase II multi-center, randomized, double-blind, placebo-controlled clinical trial is evaluating the efficacy and safety of LO2A versus placebo in patients with CCH.

Wize Pharma Chairman, Mr. Ron Mayron, said, "Completion of patient enrollment in our Phase II study of LO2A for the treatment of patients with CCH is a key milestone for Wize. This Phase II study, while conducted in Israel, is designed according to U.S. standards by a leading U.S. full-service ophthalmic clinical research organization and product development firm. As such, we believe this data may support our clinical development path for LO2A in the U.S. market."

Wize Pharma, Inc. (WIZP), closed Wednesday's trading session at $3.33, up 5.05%, on 848 volume with 4 trades. The average volume for the last 3 months is 1,964 and the stock's 52-week low/high is $0.78/$10.80.


All For One Media Corp. (AFOM)

Street Register, OTC Markets, MarketWatch,, and Barchart reported on All For One Media Corp. (AFOM), and today we report on the Company, here at the QualityStocks Daily Newsletter.

All For One Media Corp. is a tween marketing company listed on the OTC Markets. The estimation is that the tween demographic is responsible for no less than $260 billion yearly in direct sales in the United States alone. Named “Generation I” for "Internet," this generation's tweens represent the first demographic to have had only known life with the Internet and social media. In essence, All For One Media is a marketing brand changing the mindset of tweens that bullying is unacceptable. All For One Media is based in Mount Kisco, New York.

All For One Media is producing "Crazy For the Boys." The Company, through entertainment, is working to deliver a message that will resonate with kids to impact the epidemic of bullying and cyber-bullying. In addition, it is working to help individuals who have been affected by bullying to deal with it in a positive and constructive way.

“Crazy For The Boys” is a full length coming of age musical dramedy. It features Groovy Tuesday music and choreography. The film tells the story of five high school girls from five very different cliques who must work together to run their school’s anti-bullying organization. The film features original pop songs regarding peer pressure, unrequited love, and teen angst.

As part of All For One Media’s plan to build vertically integrated branded entertainment for tweens and teens, the movie is being marketed as a modern day "Grease". It will launch the new five girl pop group "Drama Drama."

All For One Media has acquired the rights to the Dream Street Master Recordings. It will be releasing them through all of the well-known digital distribution networks.

Dream Street was originally co-created by the Company’s Chief Executive Officer and President, Mr. Brian Lukow. Dream Street was one of the most popular bands of its era and still has legions of fans. All For One Media is working on a Dream Street Documentary that will document the rise and fall of the Boy Band.

All For One Media is working to make the transition from a development stage corporation creating and acquiring media assets to a content provider launching numerous initiatives this year marketed to its core tween demographic.

Over the course of this year, the Company expects to recognize revenues from the global release of Crazy for the Boys, the accompanying Soundtrack, and a touring pop group introduced to the world via the release of the movie.

All For One Media’s objective is to capitalize on a broad variety of potential revenue streams. The expectation is that “Crazy For The Boys” will generate revenues from numerous sources. These include domestic and International film distribution, video on demand, cable, pay TV and network rights, DVD and Blu-ray, corporate sponsorship, product placement, music publishing, live performance, retail and concert merchandise, music soundtracks, streaming music and videos, music downloads, third party music licenses, ad driven videos, Crazy for the Boys script licenses, spin offs and sequels.

This past February, All For One Media announced the appointment of Mr. Howard Kra as Chief Operating Officer (COO). Mr. Kra is an innovative leader and entrepreneur. His business experience spans Wall Street, Private Investment Firms, and also his own startup companies.

All For One Media Corp. (AFOM), closed Wednesday's trading session at $0.05, up 2.80%, on 395,085 volume with 17 trades. The average volume for the last 3 months is 290,851 and the stock's 52-week low/high is $0.03/$0.225.


Indoor Harvest Corp. (INQD)

Orbit Stocks, SmallCapVoice, Fast Money Alerts, Stock Shock and Awe, OTPicks, Penny Stock General, CFN Media Group, Cannabis Financial Network News, MassiveStockProfits, and PennyPickAlerts reported previously on Indoor Harvest Corp. (INQD), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

Indoor Harvest Corp. is a developer of personalized cannabis medicines. The Company is also a provider of advanced cultivation technology, methods, and processes. Indoor Harvest provides the cannabis industry production platforms for Building Integrated Agriculture (BIA) production. Listed on the OTC Markets, Indoor Harvest is based in Houston, Texas.

Indoor Harvest entered into an Agreement and Plan of Merger with Alamo CBD, on August 4, 2017. The plan completed a six-month process of work, transitioning the Company into a producer of cannabis for research and pharmaceutical development. Indoor Harvest’s patent pending aeroponic methods allow for the production of chemically consistent, contaminate free cannabis, economically at scale.

Indoor Harvest is a pending applicant under the Texas Compassionate Use Program. The Company is planning to develop facilities in the States of Arizona and Colorado.

Indoor Harvest is looking to use the relationships and technology it has developed to become a registered producer and seller under the federal Controlled Substance Act (CSA) of pharmaceutical grade Cannabis for research by third parties developing targeted treatment for specific medical symptoms.

Indoor Harvest is presently a pending applicant by way of its acquisition of Alamo CBD, to produce cannabis, under the Texas Compassionate Use program. The Company’s intention is to produce revenue from its developed facilities via leasing and licensing of its technology and methods.

Indoor Harvest and Zoned Properties, Inc. announced in October 2017 that the two companies entered into a Binding Letter of Intent (LOI) outlining three independent agreements to complete research and development (R&D) projects for licensed medical marijuana facilities to be located in Tempe, Arizona; Parachute, Colorado; and Stockdale, Texas, or other location to be determined after approval of a provisional license under the Texas Compassionate Use program. Zoned Properties is a strategic real estate development firm.

This past February, Indoor Harvest announced that Mr. Daniel Weadock joined the Company as a member of the Board of Directors and as Chief Executive Officer (CEO). Mr. Weadock replaced the Interim position held by Mr. Rick Gutshall. Mr. Weadock is Co-Founder and CEO of Junebug Technologies, LLC.

Indoor Harvest Corp. (INQD), closed Wednesday's trading session at $0.11, up 37.50%, on 790,683 volume with 150 trades. The average volume for the last 3 months is 143,120 and the stock's 52-week low/high is $0.05/$0.45.


Nutriband, Inc. (NTRB)

Stockopedia, MarketWatch, InvestorsHub, Stockhouse, Market News Updates, Morningstar, Stockwatch, Simply Wall St, GuruFocus, Barchart, InsiderMole, 4-Traders, The Street, OTC Markets, Penny Stock Hub, and Insider Monkey reported on Nutriband, Inc. (NTRB), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

A Nevada Corporation, Nutriband, Inc. is a health and pharmaceutical Company. The basis of all the Company’s products is around the science of transdermal /Topical technologies. Nutriband has its head office in Orlando, Florida. The Company lists on the OTC Markets Group’s OTCQB.

The design of Nutriband’s products is on the principle that molecular combinations can be absorbed not only orally but also through the skin. Due to the intake method, all of the Company’s products contain nothing but the bare essential ingredients. This is because there is no need for binders, fillers or unwanted animal by-products such as gelatine.

Nutriband Life Sciences is the pharmaceutical division of Nutriband, Inc. Nutriband Life Sciences centers on the development, research and marketing of unique drug delivery systems. At present, Nutriband’s drug pipeline is in formulation, feasibility, and also pre-clinical evaluation.

In April, Nutriband announced the acquisition of 4P Therapeutics, Inc. on April 5, 2018. Nutriband acquired 100 percent interest in 4P Therapeutics for a total of $1,900,000 payable in company stock and cash.  4P Therapeutics will receive 250,000 shares of common stock and a cash amount of $400,000.

4P Therapeutics will become the Pharmaceutical and Development arm of Nutriband. 4P Therapeutics will have a specific emphasis on Transdermal and Topical Technologies, prescription drugs, as well as clinical development.

Included in the acquisition of 4P Therapeutics’ Intellectual Property (IP) Portfolio is Defent™ abuse deterrent patch technology. This is an opioid abuse deterrent platform for the transdermal delivery of opioid-based medications. Defent™ reduces the risk of abuse and misuse, creating a safer treatment for patients.

Last week, Nutriband announced that it signed an exclusive 20-year; $90 million distribution agreement for its transdermal consumer product lines with Best Choice, Inc. Best Choice is a Korean consumer products distributor. Best Choice has a two decade history of working with major chain retailers.

Today, Nutriband announced that it appointed Mr. Jeff Patrick PharmD as Chief Scientific Officer and to the head of its Pharmaceutical Advisory Board.

Jeff Patrick PharmD presently serves as Director of Drug Development Institute at the Ohio State University Comprehensive Cancer Center. Most recently, Dr. Patrick served as Chief Scientific Officer for New Haven Pharmaceuticals. 

Nutriband, Inc. (NTRB), closed Wednesday's trading session at $8.04, up 1.13%, on 3,284 volume with 18 trades. The average volume for the last 3 months is 908 and the stock's 52-week low/high is $1.55/$12.70.


Thai Beverage Public Company Limited (TBVPF)

Speculating Stocks, The Subway Trader, Capital Cube, WalletInvestor, Stockhouse, YCharts, 4-Traders, wallmine, The Street, TradingView, The Stock Market Watch, OTC Markets, Stockscores, and Investors Hangout reported on Thai Beverage Public Company Limited (TBVPF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

A holding company, Thai Beverage Public Company Limited, together with its subsidiaries, produces and distributes alcoholic and non-alcoholic beverages, and food products in Thailand and around the world. Established on October 29, 2003 in Thailand, the Company operates by way of Spirits, Beer, Non-Alcoholic Beverages, and Food segments. Thai Beverage lists on the OTC Markets. The Company has its head office in Bangkok, Thailand.

The Spirits segment engages in the production and sale of spirits products. The Beer segment engages in the sale and production of branded beer products.

The Non-Alcoholic beverages segment engages in the production and sale of branded water, soda, electrolyte beverages, energy drinks, green and herbal tea, as well as ready-to-drink coffee, and fruit flavored drinks.

The Food segment engages in the operation of Japanese restaurants and the distribution of foods and beverages.  Thai Beverage’s Spirits offerings include brown spirits, white spirits, herbs, and other products.

The Company’s products additionally include carbonated soft drinks, isotonics, soya drinks, Asian and sparkling drinks, coconut water, cordials, pasteurized milk, and UHT milk. Thai Beverage also offers sterilized milk, yogurt, canned milk, pasteurized juice, ready-to-drink juice, ice cream, and cereal bars.

Moreover, Thai Beverage provides chilled and frozen food products, and snack products. It also provides oak barrels, light construction bricks, fertilizers, animal feed and supplementary animal feed, and more.

Furthermore, the Company engages in the operation of Japanese restaurants, bakeries, and social enterprise; production and distribution of biogas; and the trading of molasses. Also, it engages in the provision of advertising agency, marketing, training, consultancy, asset and brands management, transportation and distribution, procurement, and human resources (HR) and organization development services.

Thai Beverage also engages in the trading of bottles and supplies; the distribution of beverages; as well as the production of plastic packaging and related businesses.

The Company is known as ThaiBev. It is Thailand's largest and one of Southeast Asia's largest beverage enterprises. ThaiBev has distilleries in Thailand, Scotland, and the People’s Republic of China.

Thai Beverage Public Company Limited (TBVPF), closed Wednesday's trading session at $0.50656, up 2.27%, on 2,331,270 volume with 7 trades. The average volume for the last 3 months is 222,154 and the stock's 52-week low/high is $0.44/$0.746.


Applied Biosciences Corp. (APPB)

Penny Stock Hub, Stockhouse, InvestorsHub, Daily Marijuana Observer, Simply Wall St, TradingView, OTC Markets, Investors Hangout, Stockopedia, and The Stock Market Watch reported on Applied Biosciences Corp. (APPB), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Listed on the OTC Markets Group’s OTCQB, Applied Biosciences Corp. is a diversified cannabinoid therapeutics company. It centers on the on the medical, bioceutical and pet health industries. The Company was previously known as Stony Hill Corp. Applied Biosciences has its corporate headquarters in Beverly Hills, California.

On April 2, 2018, Applied Biosciences announced that it received notice of approval regarding its earlier announced name change. In addition to the name change, the Financial Industry Regulatory Authority (FINRA) approved 'APPB' as Applied Biosciences’ new ticker symbol.

The Company’s focus is on select investment, branding, real estate, and partnership opportunities in the recreational, health and wellness, nutraceuticals and media industries. Applied Biosciences products include Remedi CBD and TherPet.

The Company uses organic ingredients and formulations, which were created to target common ailments in the health and wellness industry for anyone who is open to trying hemp derived products. The products use industrial hemp as an input to produce high quality CBD for an array of health and wellness products. Remedi CBD is a line of premium hemp-derived CBD products. These products include topicals, gummies, and more.

Last month, Applied Biosciences announced that it expanded its product line and launched a hemp-derived CBD product line under the above-mentioned Remedi CBD brand. These products will be sold on Remedi's new website ( and in select locations in the United States.

At present, the new e-store offers Applied Biosciences' line of hemp-derived cannabidiol (CBD) isolate infused gummies, topicals, capsules and tinctures. The Company is continuing to launch its product lines in select specialty and retail stores.

In addition, in April, Applied Biosciences announced that it started sales of its hemp-derived CBD products on LeafLink's industry-leading B2B (Business-to-Business) e-commerce platform. LeafLink is the top B2B platform for orders, sales and relationship management for product brands and retailers.

Last week, Applied BioSciences announced that its wholly-owned animal health subsidiary, TherPet, entered the equine health marketplace with the launch of a new full-spectrum hemp-derived cannabidiol (CBD) supplement formulated specifically for a horse's health and wellness.

TherPet's Equine Care CBD line is a natural supplement. The design of it is to play a vital role in keeping horses, healthy, looking good and performing their best. The Company’s Equine Care CBD products support healthy skin, joints and immune system. These products are also for easing the discomfort of fatigued muscles, stiff joints and arthritis pain.

Applied Biosciences Corp. (APPB), closed Wednesday's trading session at $1.40, up 2.19%, on 2,450 volume with 6 trades. The average volume for the last 3 months is 1,090 and the stock's 52-week low/high is $1.00/$3.50.


The QualityStocks Company Corner

The Flowr Corporation (TSX.V: FLWR)

The QualityStocks Daily Newsletter would like to spotlight The Flowr Corporation.

The Flowr Corporation (TSXV: FLWR) today made its debut on the Toronto Stock Exchange, a significant step toward the company’s goal of “becoming one of Canada’s top licensed producers.” To read the full Forbes article, visit: To view the full press release, visit:

The Flowr Corporation (TSX.V: FLWR), a Health Canada Licensed Producer (LP) of cannabis under the Access to Cannabis for Medical Purposes Regulations (ACMPR), is an emerging Canadian cannabis leader founded by Medreleaf co-founder Tom Flow and a team of industry pioneers, successful start-up executives and top industry scientists. Flowr’s purpose-built cultivation facilities may be the most advanced in the industry, consistently generating high crop yields, delivering premium and ultra-premium cannabis products, and maximizing return on investment. The company also may be an R&D leader as it was selected by the Hawthorne Gardening Division of The Scotts Miracle-Gro Company as its exclusive Canadian cannabis R&D partner.

Flowr’s flagship facility, an 84,000-square-foot campus on seven acres in Kelowna, British Columbia, is engineered to grow premium cannabis in rooms that meet pharmaceutical industry production standards for cleanliness. This, along with exacting protocols designed by the Flowr team, enables Flowr to grow cannabis that meets Health Canada’s stringent standards without treating it with the taste- and smell-killing gamma irradiation that most other producers have to use to clean their product. Irradiating the plant – a process similar to pasteurizing food – impairs many of the important terpenes that provide the positive effects, flavors and scents of cannabis while strengthening unpleasant terpenes. Flowr’s products may deliver a better user experience, thus commanding premium prices.

Flowr’s cultivation facilities, built with proprietary, patent-pending systems, are designed to deliver yields targeted at 450 grams per square foot by the end of 2022, which is three times more efficient than the industry average of approximately 150 grams per square foot. By optimizing yield, the Company may produce significantly more cannabis flower on a smaller footprint than other producers, thus generating far high revenue per square foot and keeping costs much lower, leading to higher margins. The Kelowna facility is presently 20 percent operational with the remaining 80 percent slated to come online by early 2019. It is expected to produce up to 14,000 kg of premium, non-irradiated cannabis flower in 2019. With further enhanced yields and planned expansion of production facilities on the campus, Flowr will reach a total capacity of 60,000 kg annually in 2022.

Leading Flowr’s cultivation program is industry pioneer, company co-founder and Flowr president Tom Flow. Flow is widely recognized for his cannabis thought leadership and expertise building and operating cannabis cultivation facilities. Flow also co-founded MedReleaf and designed, built and set up SOPs for their flagship Marcum cultivation facility. Marcum has continued to be perhaps the most productive facility in the country prior to the Flowr flagship facility. Long one of Canada’s most efficient and profitable LPs, MedReleaf was acquired by Aurora for approximately C$3 billion. Flow and his team have designed and built a total of 17 cultivation facilities and secured three producer’s licenses under various Canadian regulatory regimes.

In March 2018, Flowr and the Hawthorne Gardening Division of The Scotts Miracle-Gro Company – a world leader in lawn and garden products – announced an exclusive strategic R&D alliance. After evaluating numerous Canadian LPs, Hawthorne chose to partner with Flowr based on the experience and expertise of the company’s cultivation and R&D teams and the company’s advanced growing capabilities.

Hawthorne will fund the construction of a 50,000-square-foot R&D facility that is integrated into Flowr’s Kelowna campus. This facility is North America’s first dedicated cannabis R&D facility focused on advancing cultivation techniques and systems. The facility will support researchers from both organizations and combine laboratories, indoor and greenhouse grow suites, training areas and genetics breeding areas in a single building. It is expected to open in early 2019. In addition to helping Flowr maintain its competitive advantage in cultivation, the company’s R&D program will keep it on the cutting edge of cannabis innovation.

Flowr is entering the market with three different brands to meet the growing demand for premium, non-irradiated cannabis in the medicinal and adult use markets:

  • FlowrRx, featuring premium quality medicinal cannabis that enables patients to live better, fuller lives. A dedicated Client Services team will provide patients with personalized support while an R&D team develops innovative flower strains and premium products targeted to specific conditions. Patient well-being is considered at every stage of the process – from genetic selection to harvest, trimming and curing techniques. FlowrRx and its team of passionate scientists and leading cultivation specialists are dedicated to advancing the scientific understanding of cannabis.
  • Flowr is the company’s premium recreational adult-use brand featuring an active, West Coast-inspired lifestyle for the cannabis connoisseur and enthusiast market. Through the continuous innovation of procedures and practices, Flowr’s talented team of experts is crafting premium products that deliver unparalleled experiences.
  • Ace Valley, an exclusive partnership with top-selling Ontario craft beer company Ace Hill, will bring Flowr’s premium product to the millennial and casual adult-use markets under the Ace Valley brand.

Flowr recently signed a Memorandum of Understanding with the British Columbia Liquor Distribution Branch, the province’s sole legal wholesaler of non-medical cannabis, to supply premium and ultra-premium flower to the province’s retail outlets. The company has agreements with several major medical distributors and is in discussions about retail distribution with additional provinces where it believes it can obtain prices commensurate with the quality of the Flowr products. The company is also evaluating other market opportunities including export.

Flowr is poised to become the pre-eminent indoor premium cannabis grower in Canada and one of the country’s top five LPs. The company’s focus on yield, quality and price point and its team’s ability to grow at scale should drive high margins, significant growth and strong return on investment.

The Flowr Corporation (TSX.V: FLWR), closed the day's trading session at $6.16, up 373.85%, on 1,769,312 volume with 1,635 trades. The stock's 52-week low/high is $4.00/$8.00.

Recent News


Golden Developing Solutions, Inc. (DVLP)

The QualityStocks Daily Newsletter would like to spotlight Golden Developing Solutions, Inc. (DVLP).

Golden Developing Solutions, Inc. (DVLP) was highlighted today in a report by CannabisNewsWire explaining how Judge Stephen Borrello of Michigan’s Court of Claims has issued an injunction against the state’s order to close almost 100 medical marijuana businesses that hadn’t met a section of the emergency licensing regulations passed by regulators.

Golden Developing Solutions, Inc. (DVLP), an emerging leader in ancillary software and the cannabidiol (CBD) products marketplace, provides business services and/or products supporting the cannabis industry including an online retail business for CBD, hemp oil and health/wellness related products.

Global acceptance of cannabis and related CBD products continues to increase as North America advances toward favorable legislation. Canada is set to legalize recreational cannabis in October 2018, and the United States has 30 states and the District of Columbia allowing either recreational or medical cannabis, or both. Voters in four additional U.S. states will consider marijuana initiatives on the November 2018 ballot. The global legal cannabis market is projected to reach USD$146 billion by the end of 2025, with a greater acceptance of medical cannabis products as a driving factor, according to Grand View Research.

DVLP is taking advantage of consumer demand for CBD products through its wholly owned Pura Vida Vitamins, LLC subsidiary, which recently launched a direct-to-consumer website ( and commenced sales of Pura Vida branded products. Pura Vida merchandise includes hemp and CBD-related products and other products focusing on health and lifestyle which are available through established wholesale and distribution channels. In addition, a line of CBD pet supplements and other products are in development.

DVLP recently acquired “Where’s Weed” (Layer Six Media LLC DBA “Where’s Weed”) and its primary asset,? Where’s Weed is an American cannabis technology company known for connecting medical and recreational cannabis users with trusted local marijuana businesses in their communities. As a rapidly growing community-based online resource for cannabis consumers with a host of user-friendly services, Where’s Weed offers a sophisticated mobile app with strong traction and powerful growth potential as the North American legal cannabis market continues to expand exponentially. has a large and expanding reach with nearly 3 million pageviews per month. In addition, the WheresWeed mobile app, available in both iOS and Android, has been downloaded over 80,000 times, proving to be complementary to DVLP’s objective to capitalize on the massive growth curve in the marijuana space.

“The huge flood of new growers and producers is likely to create oversupply in the near term, narrowing margins for major producers,” says DVLP CEO Stavros Triant. “However, this should actually increase the net number of new consumers in the marketplace, further reinforcing the enormous growth potential for hub service providers in the space that are situated on high-traffic internet real estate, which is exactly how we view the Where’s Weed property.”

The company’s move into the lucrative C-store snack market was solidified with a material purchase order for CBD oils from a major distributor specializing in the snack foods and accessories to the convenience store and gas station market. The order represents significant progress as DVLP gears up its ready-made snack distribution strategy for its CBD products.

“We are extremely excited about the launch of our CBD product line with this distributor,” Triant states. “The C-Store strategy dovetails perfectly with our direct marketing strategy through our primary online retail channel, and we have indications from the distributor that, if this initial test order goes well, successive Purchase Orders could be significant and underpin strong sales growth in Q1 2019.”

Golden Developing Solutions, Inc. (DVLP), closed the day's trading session at $0.035, up 34.62%, on 2,706,751 volume with 273 trades. The average volume for the last 3 months is 357,828 and the stock's 52-week low/high is $0.0125/$0.14.

Recent News


First Cobalt Corp. (TSX.V: FCC) (OTC: FTSSF)

The QualityStocks Daily Newsletter would like to spotlight First Cobalt Corp. (FTSSF).

First Cobalt (TSX.V: FCC) (OTCQX: FTSSF), a vertically integrated North America pure-play cobalt company, this morning posted the results of its first NI 43-101 Mineral Resource Estimate for the company’s 100%-owned Iron Creek Cobalt Project in Idaho. To view the full press release, visit:

First Cobalt Corp. (TSX.V: FCC) (OTC: FTSSF), with headquarters in Canada, is the largest land owner in the Cobalt Camp in Ontario with control of over 10,000 hectares (nearly 25,000 acres) of prospective land and 50 historic cobalt/silver mines. The company’s assets include a mill and the only permitted cobalt extraction refinery in North America capable of producing battery material, providing an integrated solution for cobalt projects. First Cobalt began drilling in the historic Cobalt Camp in 2017 and seeks to build shareholder value through new discovery and growth opportunities.

First Cobalt’s 2018 $C7 million drilling program, which includes testing different styles of mineralized areas throughout the Cobalt Camp in more than 10 past-producing mines known to contain cobalt, is a significant expansion over its 2017 exploration activities. The company received positive test drill results from the Bellellen mine location, with early results confirming the presence of high-grade cobalt and nickel, prompting First Cobalt to increase its drilling program at that site. A prospecting sampling program of existing muckpiles around the camp’s historic mines, trenches, pits and surrounding bedrock could provide an early production scenario.

First Cobalt Corp. is moving quickly to leverage its potential against an economic background that estimates global consumption for refined cobalt is set to grow at an average rate of approximately 5 percent per annum for the next 10 years. The electric vehicle market, in particular, is driving this sector since more than 50 percent of the world’s current production of cobalt is used in the manufacture of rechargeable lithium-ion batteries. The global lithium-ion battery market, as estimated by Zion Market Research, indicates the value at around USD $31 billion in 2016 and is expected to generate revenue of nearly USD $68 billion by end of 2022, growing at a compound annual growth rate of slightly above 17 percent.

First Cobalt is embracing innovation in the mining sector, utilizing a digital compilation of 100-plus years of mining and geological data spanning the historically prolific Cobalt Mining Camp’s lifespan. First Cobalt’s management team is also assessing the ability of artificial intelligence to accelerate the discovery cycle. As a member of the Mineral Exploration Research Centre (MERC) and Metal Earth Project, First Cobalt conducts regional geophysical surveys for geological interpretation of structures controlling cobalt-silver mineralization.

The company’s clear pathway to production and cash flow generation includes being one of only four fully permitted cobalt extraction refineries in Canada with significant material and processing infrastructure on site. With the price of cobalt increasing significantly and its importance in the growing battery market underpinning a strong long-term demand forecast, First Cobalt Corp. and its mining interests are primed for success.

First Cobalt Corp. President and CEO Trent Mell, a mining executive and capital markets professional with extensive international transactional experience, is joined by a team of reputable and seasoned deal-makers, mine builders and mine operators with decades of global experience in exploration, business development, geoscience, engineering and finance.

First Cobalt Corp. (FTSSF), closed the day's trading session at $0.2741, up 11.79%, on 202,924 volume with 105 trades. The average volume for the last 3 months is 205,989 and the stock's 52-week low/high is $0.1983/$1.3041.

Recent News


Youngevity International, Inc. (NASDAQ: YGYI)

The QualityStocks Daily Newsletter would like to spotlight Youngevity International, Inc. (YGYI).

With Canada legalizing cannabis nationwide in October and the 2018 U.S. Farm Bill completely removing hemp from the DEA’s controlled substances list, the stage has been set for an explosion of products ranging from functional foods and supplements to CBD-based (cannabidiol) biopharma indications. Even before the landmark inclusion of the Hemp Farming Act of 2018 in this year’s Farm Bill, plant-based nutrition experts at leading omni-direct lifestyle company Youngevity International, Inc. (NASDAQ: YGYI) had begun marching the team towards the development of a full line of proprietary hemp-derived CBD oil products.

Youngevity International, Inc. (NASDAQ: YGYI) is a leading omni-direct lifestyle company offering a hybrid of the direct selling business model that includes e-commerce and the power of social selling. Among the Top 100 Global Direct Selling Companies, Youngevity offers products from the six top selling retail categories: health/nutrition, home/family, food/beverage (including coffee), spa/beauty, apparel/jewelry, and a range of innovative services. Created through the 2011 merger of Youngevity Essential Life Sciences with Javalution® Coffee Company, today’s Youngevity International Inc. is a virtual worldwide Main Street of products and services under one corporate entity that supports a healthy and empowered lifestyle.

Youngevity International is dedicated to improving lifestyles through the universal desires of vibrant health and flourishing economics. Catering to health-conscious consumers, Youngevity believes that combining the best of the direct selling industry with the fundamentals and capabilities of a traditional business model will maximize shareholder value. The company’s Nutritional, Lifestyle and Telecommunications products and services are distributed through a global network of Preferred Customers and Distributors.

Youngevity’s wholly owned CLR Roasters LLC business line offers quality branded and private label coffee to retail stores, office coffee services, hospitality, food services, distributors, convenience, petrol stores and vending businesses. Today, CLR Roasters is the largest coffee provider for cruise lines in North America and the second largest roaster in the state of Florida. Producing a consistent premium product with superior taste, CLR Roasters has earned numerous certifications that demonstrate the company’s commitment to the craft of providing the highest quality coffee products using the best practice standards available.

Youngevity, operating in the direct-selling channel, is rapidly expanding its product and distributor base through acquisitions and mergers under an innovative concept called “the Network Cloud” that provides other direct selling companies with a home base. The company’s YoungevityGO2 mobile distributor app, a new technology-driven web platform supporting expansion of global e-commerce and social selling platforms, is available on Google Play and the App Store. In addition to the Network Cloud concept, Youngevity International owns CLR Coffee Roasters which operates a traditional coffee roasting business offering a JavaFit® gourmet product line that vertically integrates with Youngevity and its growing network of direct marketers.

Youngevity International offers more than 1,000 high quality, technologically advanced products under the following categories:

  • Health and Nutrition
  • Home and Family
  • Food and Beverage
  • Spa and Beauty
  • Fashion
  • Essential Oils
  • Photo and scrapbooking
  • Services for Home and Business

Youngevity International Inc. has compiled a best-in-class management team with a strong track record of success in private and public companies. Steve Wallach, CEO, has nearly two decades of sales and network marketing experience and has successfully guided Youngevity International Inc. to become an international, publicly-traded direct marketing company positioned for worldwide growth. Dave Briskie, president and CFO, has shepherded the company’s development into a fully vertical coffee roasting and distribution company that owns the direct marketing brand JavaFit® and the retail brand, Café La Rica.

Youngevity has also attracted a stunning group of Brand Evangelists who endorse its products. Among these are actress, author and well-known health and wellness activist Marilu Henner; former NBA basket player, Mike “Stinger” Glenn; former NFL wide receiver Drew Pearson; “Greatest Natural Bodybuilder in the World” Gene Nelson; and WNBA champion, Olympic gold medalist Delisha Jones.

Youngevity International, Inc. (NASDAQ: YGYI), closed the day's trading session at $6.20, up 13.55%, on 209,920 volume with 739 trades. The average volume for the last 3 months is 35,465 and the stock's 52-week low/high is $3.17/$6.55.

Recent News


BriaCell Therapeutics Corp. (OTC: BCTXF) (TSX.V: BCT)

The QualityStocks Daily Newsletter would like to spotlight BriaCell Therapeutics Corp. (BCTXF).

BriaCell Therapeutics Corp. (OTC: BCTXF) (TSX.V: BCT), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, is pleased to announce that it has achieved proof of concept in the Phase IIa study of its lead clinical candidate, Bria-IMT™, in advanced breast cancer. The Company will host a webcast at 4:15 p.m. ET today to discuss these results.

BriaCell Therapeutics Corp. (OTC: BCTXF) (TSX.V: BCT), based in Berkeley, CA, and headquartered in Vancouver, British Columbia, is a clinical-stage biotechnology company focused on the development of targeted immunotherapy for advanced breast cancer.

BriaCell hopes to develop and market the first off-the-shelf personalized immunotherapy for the treatment of advanced breast cancer.

The results of two previous proof-of-concept clinical trials produced encouraging results in patients with advanced breast cancer. Most notably, one patient with breast cancer that had spread to other sites (metastatic cancer) responded to Bria-IMT™ with a substantial tumor shrinkage in multiple sites including the breast, the lung, soft tissues and even the brain. Similar observations have been confirmed more recently in additional patients, and BriaCell is developing BriaDX™ as a way to identify those patients most likely to respond.

BriaCell has recently completed recruitment of a Phase I/II study (NCT03066947) of Bria-IMT™, the Company’s lead product candidate, in advanced breast cancer patients showing an outstanding safety profile and excellent efficacy. BriaCell is currently enrolling advanced breast cancer patients in a combination therapy trial (NCT03328026) of Bria-IMT™ with Keytruda® (Keytruda® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.) or Yervoy® (Yervoy® is a registered trademark of Bristol-Myers Squibb Company). For further information on the Phase IIa clinical trials, please visit trial NCT03066947 and trial NCT03328026.

BriaCell’s pipeline also includes Bria-OTS™, the first off-the-shelf personalized immunotherapy for advanced breast cancer; and, a companion diagnostic product BriaDX™. By using BriaDX™ to identify and treat the patients who would most likely benefit from their immunotherapies, BriaCell expects to personalize the treatment for the patients, and bring hope to thousands of cancer patients who currently have few-to-no treatment options.

Breast Cancer Statistics

The National Cancer Institute estimates that more than 265,000 new cases of female breast cancer will be diagnosed in the U.S. during 2018, and that more than 40,000 women in the U.S. will die from the disease. Approximately 12 percent of women will be diagnosed with breast cancer at some point during their lifetime, based on 2013-2015 data.

Using its novel technology platform and strong R&D capabilities, BriaCell believes it has the opportunity to address this market, as well as have the opportunity to develop immunotherapy candidates for other cancer indications.

The global cancer immunotherapy market is expected to reach nearly USD$203 billion by 2025.

BriaCell Therapeutics Corp. (BCTXF), closed the day's trading session at $0.1137, up 12.90%, on 1,200 volume with 2 trades. The average volume for the last 3 months is 15,039 and the stock's 52-week low/high is $0.068/$0.139.

Recent News


Earth Science Tech, Inc. (ETST)

The QualityStocks Daily Newsletter would like to spotlight Earth Science Tech, Inc. (ETST).

SeeThruEquity, the leading independent equity research firm focused on smallcap and microcap public companies, today announced it has issued an update note on Earth Science Tech, Inc. (OTCQB: ETST). The report is available here: ETST Update Note.

Earth Science Tech, Inc. (ETST) is an innovative biotechnology company operating in the fields of hemp cannabinoid (CBD), nutraceutical, pharmaceutical and medical device research and development. Earth Science Tech offers the highest purity and quality, full-spectrum, high-grade hemp CBD (cannabidiol) oil on the market. Made using the supercritical CO2 liquid extraction process, the company’s CBD oil is 100 percent natural and organic. Earth Science Tech has partnered with the University of Central Oklahoma and DV Biologics Laboratory to conduct research and development projects that scientifically support and advance the healthcare benefits of its high-grade hemp CBD oil.

Earth Science Tech Inc. currently has three wholly owned subsidiaries focused on developing its role as a world leader in the CBD space and expanding its work in the pharmaceutical and medical device sectors. These subsidiaries include:

  • Earth Science Pharma, Inc., which is committed to development of low cost, noninvasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted infections and/or diseases. Earth Science Pharmaceutical CEO and chief science officer Michel Aubé is leading the company’s research and development efforts. The company’s first medical device, MSN-2, is a home kit designed for the detection of STIs, such as chlamydia, from a self-obtained gynecological specimen. Earth Science Pharma is working to develop and bring to market medical devices and vaccines that meet the specific needs of women.
  • Cannabis Therapeutics, Inc. (“CTI”), which is poised to take a leadership role in the development of new, leading-edge, cannabinoid-based pharmaceutical and nutraceutical products. CTI is invested in research and development to explore and harness the medicinal power of cannabidiol. The company holds a provisional application patent for a CBD product that is focused on developing treatments for breast and ovarian cancers.
  • KannaBidioiD (“KBD”) provides a wide variety of products geared toward the recreational space of cannabis. KBD’s unique Kanna and CBD formulation is sold and distributed in CBD-infused edibles and vapes/e-liquids products. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhanced focus and the added benefit of assisting with nicotine reduction therapy.

Earth Science Tech celebrated a significant, developmental year during 2017 by sharing its achievements in a condensed end-of-year report. Among the report’s highlights are the implementation of a development plan for the coming three years, which includes expanding into Canada and opening new manufacturing and shipping facilities. Of particular interest is the acquisition of Canna Inno Laboratories Inc., a company headquartered in Montreal, Quebec, Canada, which gives Earth Science Tech access to Canadian government grants offered to innovators in the pharmaceutical industry. ETST has also launched development of proprietary prophylactic therapies utilizing cannabidiol (CBD) to treat various forms of breast cancer.

In October 2017, ETST announced it is cooperating with the Clinique SIDA Amité (AIDS Friendship Clinic) for a mini-clinical trial, the last trial needed before the MSN-2 device, designed for the detection of STIs, enters molecular diagnostic trials. And in November 2017, the company began pre-launch human trials on a new CBD formula to fight against the U.S. opioid epidemic. The new formula, expected to decrease cravings and the negative effects of withdrawal in addicts, is based on industrial hemp CBD mixed with a known natural ingredient proven to help increase dopamine levels. ETST’s medical devices will first be launched in Vietnam, Djibouti and Morocco while the company awaits regulatory permission to enter the North American market.

The company expects to up-list to the OTCQB in early 2018, which management believes will attract well-funded institutional investors and pave the way to becoming the next billion-dollar-in-capitalization company on the OTC markets. Other highlights include completion of the company’s Scientific Advisory Council with a team of recognized scientists, the launching of several CBD-infused edible products and entry into the medical devices market through collaborative partnerships.

Earth Science Tech has signed a collaborate agreement with Laboratories BNK Canada, a private laboratory that will conduct the clinical studies necessary for MSN-2 medical device-related services to meet regulatory requirements. ETST has confirmed the MSN-2 device’s ability to detect chlamydia, and is working to validate similar results for gonorrhea, both highly infectious diseases that often have permanent consequences for patients. ETST will also add testing for trichomoniasis and a complete body fluid panel to detect the different serotypes of the human papillomavirus (HPV) that causes cervical cancer. These additions will help the company create sales opportunities in the global market for diagnostic testing of STDs that Transparency Market Research has indicated will grow to $108 billion by 2019.

Cannabis Therapeutics is in the development stage of two cannabinoid-based pharmaceutical drugs and three cannabinoid-based nutraceutical products targeting a variety of ailments such as anxiety, depression, triple negative breast cancer, and fatty liver disease, among others. Research into the benefits of the non-psychoactive cannabinoid molecules found in the cannabis plant is supported by ETST’s International Application for Provisional Patent titled “Cannabidiol Compositions Including Mixtures and Uses Thereof,” which was filed on October 8, 2015. Cannabis Thera’s R&D efforts are concentrated on developing CBD-based drugs and nutraceutical products and in working to integrate the CBD molecule with existing generic drug molecules to create more efficient medications with fewer and less severe side effects. A report in Hemp Business Journal predicts the CBD consumer market will grow to $2.1 billion by 2020, while other industry experts expect an increase to almost $3 billion by 2021. A recent report by Statista projects the U.S. consumer market for cannabinoid-based pharmaceuticals could reach $50 billion by the year 2029.

The management team at Earth Science Tech brings decades of invaluable experience to the nutraceutical, dietary supplement field as well as the life sciences sectors. Nickolas S. Tabraue, who serves as the president, director and chief operating officer, is an industry veteran with extensive knowledge of supplements, retail management, customer service and sales expertise. He is joined by CEO and CSO Dr. Michel Aubé, a microbiologist whose scientific research in sexually transmitted infections, cancer and stem cell biology has been widely published in several prestigious medical journals. Sergio Castillo, chief marketing officer, and Gabriel Aviles, chief sales officer, bring a wealth of marketing and sales experience to Earth Science Tech, which is complemented by Issa El-Cheikh, Ph.D., and his 25 years in the international finance, accounting, planning and execution of large scale transactions in the public and private sectors.

Earth Science Tech’s products include CBD, a natural constituent of hemp oil derived from hemp stalk and seed. EST offers CBD in the form of vitamins, minerals, herbs, botanicals, personal care products, homeopathies, functional foods and other products delivered in such forms as capsules, tablets, soft gels, chewables, liquids, creams, sprays, powders and whole herbs. Earth Science products can be found at retail stores throughout the United States and are available for purchase through the internet.

Earth Science Tech, Inc. (ETST), closed the day's trading session at $1.086, up 4.42%, on 61,106 volume with 78 trades. The average volume for the last 3 months is 25,040 and the stock's 52-week low/high is $0.324/$1.62.

Recent News


VIVO Cannabis Inc. (TSX.V: VIVO) (OTC: VVCIF)

The QualityStocks Daily Newsletter would like to spotlight VIVO Cannabis Inc. (VVCIF).

VIVO Cannabis Inc. (TSX-V: VIVO, OTCQB: VVCIF) (“VIVO” or the “Company”) is pleased to announce that it has completed the construction of its first innovative seasonal “Airhouse”. Also today, CannabisNewsWire released a report highlighting the company, detailing how Judge Stephen Borrello of Michigan’s Court of Claims has issued an injunction against the state’s order to close almost 100 medical marijuana businesses that hadn’t met a section of the emergency licensing regulations passed by regulators.

VIVO Cannabis Inc. (TSX.V: VIVO) (OTC: VVCIF) is a globally licensed, cost efficient producer of premium quality, organic, standardized medicinal cannabis. One of the earliest licensed medical marijuana producers under Canada’s federally-controlled Access to Cannabis for Medical Purposes Regulations (ACMPR), VIVO has five years of operating experience in the burgeoning medical marijuana space through its flagship operation, ABcann Medicinals, Inc. The company recently received its Health Canada license to produce medical cannabis oils and is working toward production of saleable, extracted, finished products that will lead to a final inspection allowing sales of its oils.

“Receipt of the license to produce cannabis oils is a major milestone in our pursuit to provide our medical cannabis patients with additional product formats that can be precisely dosed. The expansion and innovation of our product lines are a top priority for the Company as we continue to serve the needs of our customers, and we anticipate strong demand for our cannabis oil products,” VIVO CEO Barry Fishman said.

VIVO owns and operates a fully functioning 14,500 square foot facility in Napanee, Ontario, which is being doubled in size to produce 1,400 kg of cannabis per year. The company’s expansion plans include adding a seasonal greenhouse and a hybrid, multipurpose facility, capable of producing 31,000 kg of cannabis per year between the two facilities, to be constructed on 65 acres it already owns near the Napanee facility. This additional location is properly zoned with existing infrastructure in place for an eventual 1.2 million square feet of production space.

VIVO has built a reputation over the years for its best-in-class standardized approach to growing cannabis that includes the absence of pesticides and a computer monitored growing technique that provides a consistent, pharmaceutical-grade with high yields. The company’s custom, scalable growing chambers with proprietary lighting can be replicated anywhere in the world, leading to lower production costs. This technique has helped it record a customer retention rate of 94.7 percent alongside 30 percent month-over-month customer growth. When combined with VIVO’s current yield rate, which it has measured at roughly 100 percent greater than the industry average, the company has constructed a strong foundation upon which to build a sizable presence in the global cannabis industry.

This global growth potential is illustrated by VIVO’s partnership with Israel’s Syqe Medical, producer of the world’s first selective-dose pharmaceutical grade medicinal plant inhaler. After visiting VIVO’s production facility, Perry Davidson, founder of Syqe Medical, noted that the company’s production technologies put it “in a class with the best in the world” in its ability to produce standardized pharmaceutical grade cannabis.

VIVO’s recent acquisition of Harvest Medicine Inc. represents further progress toward the company’s goal of becoming a vertically integrated medical cannabis company. Harvest Medicine is one of the fastest growing medical cannabis clinics in Canada – adding over 1,200 new patients monthly from a single location – with an aggressive expansion plan and a patient-focused approach that perfectly aligns with VIVO’s philosophy of quality and innovation.

VIVO’s seasoned management team, board of directors and advisory board features well over a century of combined industry experience. Fishman, who has over 20 years of experience as a business leader, previously served as CEO of both Teva Canada and Taro Canada, as vice president of marketing at Eli Lilly Canada, and as past chair of the Canadian Generic Manufacturers Association. He most recently served as CEO of international specialty pharmaceutical company Merus Labs.

Notably, VIVO also has access to the ‘Father of Cannabis Research’, Raphael Mechoulam, PhD, through its board of advisors. An organic chemist and professor of medicinal chemistry at the Hebrew University of Jerusalem, Mechoulam was the first scientist to isolate both cannabidiol (CBD) and tetrahydrocannabinol (THC). He has received more than 25 prestigious academic awards, including the Rothschild Prize in Chemical Sciences and Physical Sciences in 2012.

With more than 65 acres of growth capacity, a healthy cash balance to fund upcoming construction efforts, steady sales growth, industry-leading yield rates and an established operations team in place, VIVO is well positioned to compete in the rapidly expanding Canadian cannabis industry and beyond.

VIVO Cannabis Inc. (VVCIF), closed the day's trading session at $1.24, up 2.48%, on 327,057 volume with 373 trades. The average volume for the last 3 months is 708,766 and the stock's 52-week low/high is $0.725/$3.293.

Recent News


Choom Holdings Inc. (CSE: CHOO) (OTC: CHOOF)

The QualityStocks Daily Newsletter would like to spotlight Choom Holdings Inc. (CHOOF).

Choom Holdings Inc. (CSE: CHOO) (OTC: CHOOF) was highlighted today in an article discussing how rising overall excitement building in the Cannabis markets is everywhere as many are keeping a close eye on the massive global potential of the marijuana industry as legalization is just days away in Canada.

Choom Holdings Inc. (OTC: CHOOF) (CSE: CHOO) channels the laid-back spirit of Hawaii to the Okanagan region of British Columbia with a generous nod to the inspirational, yet unofficial, history of the 1970s “Choom Gang,” a group of buddies in Honolulu (including former President Barack Obama) who knew how to relax with “choom,” the local’s term for marijuana. Choom’s trademark slogans pivot off another unconventional phrase (“Say Hello to…”), bringing a heady dose of good times and good friends together as the company invites investors to “Say Hello to Choom™” as it lights up the adult recreational cannabis market in Canada.

Choom™ has been an ACMPR (Access to Cannabis for Medical Purposes Regulations) applicant since November 2013 in Vernon, B.C. The company’s first application has received security clearance and is now in the detailed review stage. They also recently announced their second late-stage ACMPR application, which is in its confirmation of readiness stage. Cannabis Compliance Inc. has been retained to help expedite Choom’s initial license applications to ensure the company’s readiness for legalization of recreational marijuana in Canada mid-summer 2018.

True to the company’s character, Choom™ is retrofitting two large facilities – No. 1 in Vernon, B.C., and No. 2 on Vancouver Island – to house its cannabis growing facilities. Phase 1 of the Vernon property will provide Choom™ with 6,800 square feet of growing space, capable of producing 660 kg/year of cannabis at an estimated revenue of $6.6 million, excluding oils. The company expects this facility to be completed by July 2018, the same month that Canada is expected to formally legalize recreational marijuana for adult use. A potential Phase 2, to be completed by the end of 2018, would add another 6,800 square feet for a total of 1,500 kg/year capacity, which would nearly double No. 1’s revenue. A Level 9 vault is also planned with a storage capacity of 15,000 kg. While the No. 2 facility on Vancouver Island is smaller – 4,500 square feet – its retrofit is also slated to be completed by July 2018. Plans include doubling this space as well, which would add about $9 million in annual revenue, excluding cannabis oils.

Choom™ announced its retail dispensary strategy with the intention of establishing market leadership in reaching the Canadian cannabis consumer. The partner program is already in the retail space design stage as the company seeks to build a chain of branded retail cannabis dispensaries in jurisdictions in Canada where recreational cannabis is legal. Choom™ Stores will have a cool, modern layout and design created to emit an authentic “Aloha” vibe. Choom™ is all about producing high-grade cultivars and curating them for a bigger audience.

A savvy, experienced management team includes Chris Bogart, president and CEO; John Oh, R.P.I.C., Operations Manager; Robert Bayrack, Master Grower, S.P.I.C.; and Adrian Robinson, Strategic Advisor. Bogart has over two decades of international experience in capital markets and was a co-founder of InMed Pharmaceuticals and Magnum Uranium. He has structured complex equity financing transactions in the U.S., Europe and Canada. Bogart is joined on the Board of Directors by Kevin Pull, Stephen Tong and John Oh.

While the medical marijuana industry is expected to double by 2021 to 500,000 registered users, the true highlight of the recreational cannabis represents the key cultural shift set to launch in Canada. With an estimated $4.9B to $8.7B retail market coming, now is the right time for a Recreation Brand like Choom™ to be involved in this growing industry. Establishing and maintaining Choom™ premium brand loyalty is a key factor in the company’s growth strategy. Get ready to “Say Hello” to opportunity, good times and good friends with Choom™.

Choom Holdings Inc. (CHOOF), closed the day's trading session at $0.90, up 1.11%, on 358,170 volume with 380 trades. The average volume for the last 3 months is 294,816 and the stock's 52-week low/high is $0.18/$1.13.

Recent News


Marijuana Company of America Inc. (OTC: MCOA)

The QualityStocks Daily Newsletter would like to spotlight Marijuana Company of America Inc. (MCOA).

CannabisNewsWire ("CNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring Marijuana Company of America Inc. (OTC: MCOA), a client of CNW that focuses on product research and development of legal hemp-based consumer products containing CBD under the brand name “hempSMART™”, an affiliate marketing program to promote and sell its products, as well as leasing of real property and expansion of business into ancillary areas of the legalized cannabis and hemp industry. To view the full publication, titled “Something for Everyone: Baby Boomers Signify Shift in the Cannabis Market,” visit:

Marijuana Company of America Inc. (OTC: MCOA) (the “Company”) are pioneers in the cannabis industry going back to 2009 when Don Steinberg, MCOA’s CEO, founded the first marijuana company ever to trade on a U.S. stock market, Medical Marijuana Inc. Since then, Don and his partner, Charlie Larsen, have formed Global Hemp Group and Marijuana Company of America. They have experienced the shift of legislation first hand, not only for the legalization of marijuana but also the emerging hemp-based CBD products.

The CBD market is growing exponentially and consequently the founders of MCOA have constructed their business model around the development of industrial hemp-based CBD products. The industrial hemp plant can be used to produce products that are carbon neutral or even carbon negative. It is one of the longest, strongest natural fibers on earth, used as a building material that is free of mold, pesticide-resistant, and fire proof. Hemp has also been described as a “super food,” which provides additional business opportunities. No part of the plant is left unused and the Company’s overall strategy is to take advantage of every profit center from farm to the multiple valuable finished products.

The cannabis and hemp industries are experiencing unprecedented growth that is expected to continue for many years as these industries are now accepted globally and continue to mature and expand. North American consumers spent $6.7 billion on legal cannabis products in 2016, up 34% from 2015’s $5 billion. This trend is widely expected to explode at a 27% compounded annual growth rate to reach $22.6 billion by 2021, according to ArcView Market Research.

The company offers investors the opportunity to be on the forefront of cannabis and hemp innovation through cultivation, processing in the legal cannabis and industrial hemp sectors. The Company’s business model includes producing a diverse portfolio of synergistic business segments that provide value to its shareholders. Its vertically integrated business model and distribution platforms are positioned to capture market share by developing recognizable and valuable brands.

Under the MCOA umbrella, wholly owned subsidiary hempSMART™, Inc. is committed to bringing high quality CBD-based products to the market through its affiliate marketing program. Through hempSMART, MCOA’s strategic approach to the distribution of products is through a networking architecture geared to maintain customer loyalty and capture market share. The patent-pending product “hempSMART Brain,” is designed to revolutionize the safe and effective support of healthy brain function. The brand new product, HempSMART DROPS, is a full-spectrum CBD tincture formulated with hemp and fractionated coconut oils. The hempSMART marketing team has decades of experience, and is well positioned to take the hempSMART brand to a global audience.

Marijuana Company of America Inc. (MCOA), closed the day's trading session at $0.0264, off by 1.86%, on 6,802,245 volume with 337 trades. The average volume for the last 3 months is 7,878,131 and the stock's 52-week low/high is $0.022/$0.073.

Recent News


Pacific Software, Inc. (PFSF)

The QualityStocks Daily Newsletter would like to spotlight Pacific Software, Inc. (PFSF).

With the development of its blockchain ecommerce trade platform, Pacific Software, Inc. (OTC: PFSF) offers the prospect of supply chains with a level of transparency and integrity that is sorely lacking in current systems.

Pacific Software, Inc. (PFSF) is focused on the design, development, and distribution of Hyperledger blockchain technology solutions for application to the specific needs of agriculture, cannabis, and the opioid epidemic.

The basic requirements of the systems to be developed include high-throughput transaction processing, traceability or tracking, visibility or monitoring, and transparency throughout the supply and value chains for the stakeholders. The development of this architecture will serve as an online commercial portal to service Pacific Software’s B2B accounts in the sectors below.

For application of its Agri-blockchain based system, Pacific Software will target farm-to-consumer exports to increase transparency, combat theft and counterfeit products, and reduce the health risks associated with shipping “tainted” agricultural products to other countries.

Perceiving blockchain as an ideal mechanism for the complexities of the cannabis industry, Pacific Software will strive to improve the transparency, compliance, and efficiency of the “seed-to-sale” supply chain in states where the plant is legal.

Controlled Substances
With the misuse of opioids on the rise worldwide, Pacific Software aims to apply its blockchain-based system to track opioids from pharmaceutical production to consumers and attempt to identify “Bad Actors” in the supply chain and fight against the global epidemic.

Business Model
The portal will be structured in a B2B format where clients will pay the company transaction fees, royalties, cash, cash equivalents and other forms of compensation to utilize its Hyperledger blockchain applications for their business models.

As the company executes these strategies, each Hyperledger blockchain-based system designed may be organized separately in wholly owned subsidiaries. To enhance its portfolio of holdings, Pacific Software may consider investments in companies where selected markets have imminent profitable results, providing appreciable value for investors and shareholders.

Pacific Software, Inc. (PFSF), closed the day's trading session at $5.25, even for the day. The average volume for the last 3 months is 3 and the stock's 52-week low/high is $0.031/$7.13.

Recent News


Sugarmade, Inc. (SGMD)

The QualityStocks Daily Newsletter would like to spotlight Sugarmade, Inc. (SGMD).

CannabisNewsWire ("CNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring Sugarmade, Inc. (OTC: SGMD), a client of CNW focused on investment in products and brands with disruptive potential. To view the full publication, titled “Hydroponic Hardware Key to Tapping Long-Term Profits of Burgeoning Cannabis Market,” visit:

Sugarmade, Inc. (SGMD) one of the largest publicly traded hydroponics supply companies moving into the industrial hemp space, is a product and brand marketing company investing in products and brands with disruptive potential. Sugarmade’s brands include:;; and BudLife. Headquartered in Monrovia, California, a city within Los Angeles county, Sugarmade has various business operations in diverse marketplaces including packaging and paper goods for various industries, agricultural supplies.

Sugarmade has expanded into the European hydroponics supply market with a growing base of orders taken through Amazon UK. Over the past few financial quarters, Sugarmade has seen revenue growth patterns expand geographically. As recently as mid-2017, the majority of hydroponic-related revenue growth was seen from California and other West Coast marketplaces, however growth is becoming more geographically dispersed among U.S. states where legalization has eased restriction. This movement into the United Kingdom further expands the base of geographic growth areas for Sugarmade.

Sugarmade recently launched a new corporate initiative in the booming industrial hemp and CBD, committing up to $1 million in capital over the next 12 months to invest in Hempistry, Inc., a privately held Nevada corporation. Hempistry has begun planting an ultra-high cannabidiol (CBD) industrial hemp strain on a land option it holds on 23,000 acres of prime Kentucky farmland. The strain of industrial hemp being grown by Hempistry is ultra-rich in CBD but contains less than 0.3 percent of THC, the psychoactive ingredient found in cannabis. The U.S. hemp industry is expected to produce well over $1 billion in revenues in 2018, with a compound annual growth rate of 14 percent through 2022, according to the Hemp Business Journal.

Demand for industrial hemp and products derived from hemp is soaring, with no let-up in sight, which the company sees as a “tremendous opportunity to become a supplier to this fast-growing sector,” said Chairman and CEO Jimmy Chan, who is also an advisor and minority shareholder of Hempistry.

Sugarmade’s investment into the market for high-CBD hemp is expected to be highly accretive for common shareholders in two ways. First, Sugarmade’s investment will be in the form of common shares in Hempistry allowing Sugarmade common shareholders to possibly benefit from any future initial public offering of Hempistry. Second, Sugarmade is expected to sign a supply agreement with Hempistry for cultivation supplies, which would be additive to corporate revenues.

Sugarmade has also completed a master market agreement with industry leader BizRight Hydroponics, Inc., a leading marketer and manufacturer of cannabis and hydroponic growth supplies, which offers a range of hydroponics-related products including: HPS grow lights, electronic ballasts, HPS bulbs, nutrient mixes, environmental control products, pH measurement and calibration solutions and storage products. BizRight operates the website and other e-commerce properties and sells various products to distributors and retailers. BizRight is expected to produce in excess of $30 million in revenues during 2017, with substantial growth expected for 2018.

Sugarmade division, the leader in paper and plastic take-out supplies, serves nationwide customers by offering a wide array of high quality products that are cost-efficient, custom-made and delivered on time. This business unit currently serves 2,000 quick service restaurants, garnering from 30-40 percent of the market share. Sugarmade plans to expand operations via the addition of market share and the introduction of new product offerings.


CEO Jimmy Chan is an experienced business executive instrumental in growing multiple business operations with a strong expertise in international trade and banking, and international manufacturing and importation. He is also the founder of, a company that revolutionized the custom-printed paper supplies subsector of the quick service restaurant industry, which merged with Sugarmade in 2014.

Arman Tabatabaei serves as operations consultant, providing high-level, day-to-day strategic guidance and tactical operational supervision for all aspects of the corporation’s business. He is an expert at data collection and analysis relative to resource management, risk forecasting and profit and loss management.

Sugarmade specializes in growing and acquiring innovative brands to maximize value for company employees, shareholders and other stakeholders. Sugarmade believes its future is very bright as the company expands operations within the cultivation sector and rapidly increases its revenue base.

Sugarmade, Inc. (SGMD), closed the day's trading session at $0.092, even for the day, on 3,109,740 volume with 247 trades. The average volume for the last 3 months is 1,522,209 and the stock's 52-week low/high is $0.028/$0.43.

Recent News


BLOCKStrain Technology Corp. (TSX.V: DNAX) (OTC: BKKSF)

The QualityStocks Daily Newsletter would like to spotlight BLOCKStrain Technology Corp. (BKKSF).

The nascent industries serving state-by-state cannabis legalization in the United States are feeling growing pains as they deal with the costs of delivering safe and quality-tested products to consumers. In this new age of plant-drug liberalization, BLOCKStrain Technology Corp. (TSX.V: DNAX) (OTC: BKKSF) is offering hope of some ground-level security to the product pipeline, so consumers can distinguish between potentially healthful cannabis and potentially low-quality products.

BLOCKStrain Technology Corp. (TSX.V: DNAX) (OTC: BKKSF), a full-service software company headquartered in Vancouver, BC, Canada, has developed the first integrated blockchain platform that registers and tracks cannabis intellectual property (“IP”) from genome to sale. It is proprietary, immutable and cryptographically secure, thereby establishing a single source of truth for cannabis strains and their ownership.

With Canada set to legalize marijuana use for recreational purposes, and other jurisdictions following suit around the world, new challenges will emerge regarding the ability to provide a safe and legal inventory of a product that up until now was largely only available on the black market. Cannabis will be heavily tested and regulated by numerous regulatory bodies in Canada. The cannabis industry faces unique challenges that BLOCKStrain specifically helps it address, including:

  • Mandatory Testing: Through BLOCKStrain’s platform and lab-testing partners, the process is more efficient and streamlined, cutting the administrative burden in half and getting products to market faster;
  • DNA Based Product Validation: The underlying blockchain technology creates a genetic fingerprint that identifies and validates the product electronically so any participant on the platform, including consumers, can view and track what’s happening with that product from genome to sale;
  • Intellectual Property: Third, and perhaps most importantly, the BLOCKStrain platform protects the intellectual property of growers and breeders. This is important for the industry’s growth as products evolve and develop. If a craft grower, for example, creates a popular strain with unique characteristics, it will be able to protect its intellectual property by simply registering the strain’s genome with BLOCKStrain and locking that data into the blockchain. It will reside there forever and will be readily accessible in the event of future disputes, bringing a level of trust to the industry and ensuring licensing fees are paid to all players in the market.


BLOCKStrain’s genetics verification process is authentic and incredibly effective. User groups register by creating an account with BLOCKStrain, which starts the process. Organizations and independent growers submit seeds, flower and post-extraction product for testing to a registered and approved testing facility, which then submits test results to BLOCKStrain. Pre-existing data of genetic cannabis strains can also be submitted via BLOCKStrain verification administrators, with those results being added to the user group’s blockchain account. Submissions are entered into BLOCKStrain, and the transaction is completed and recorded.

Each time an item is tested and verified by the network, a Registration Affidavit is auto-generated and given a unique “BLOCKStrain Address” along with a traceable QR Code. Producers, patients and consumers are able to not only verify the test but can also rate the product, write reviews and share opinions. This detail is stored within BLOCKStrain and, just like the test results, cannot be tampered with or modified. Verification and certification are earned by all parties for their participation.


BLOCKStrain demystifies the seed-to-sale process for all relevant stakeholders including producers, distributors, shippers, government agencies and consumers by creating a repository of cannabis genomes on an immutable, shared ledger. Thousands of cannabis strains exist and cultivators are breeding new strains all the time. The proliferation of cannabis strains can prove problematic for consumers since there are more than 500 known chemical compounds in a single plant. Furthermore, since several dozens of these compounds have been identified as pharmacologically active, it becomes more and more difficult for consumers to know what they are purchasing.

It is for this reason that being able to quantify the genetics, potency and equivalencies among cannabis products is crucial to the future of legalized cannabis. The difference is not so much in the name or brand attached to the cannabis, but the DNA of the plant itself. BLOCKStrain ensures product integrity, safety, regulatory compliance, product licensing and authenticity – all vital elements for the emerging cannabis industry.  This technology also bolsters the process of meeting government regulatory standards by providing real-time visibility of industry operations to agencies assigned to enforce and regulate cannabis activity.


BLOCKStrain allows for the defense of intellectual property rights for the grower with an authentic, verifiable chain of evidence embedded in the blockchain itself. Proof of ownership for a specific strain of cannabis is paramount in a multibillion dollar industry. Real life ownership disputes have already begun in the industry with legal battles underway. Unfortunately, the framework for resolving these disputes has yet to be defined and they are not likely to be resolved anytime soon.

Consumers and regulators alike want to know whether a cannabis product grown and sold at a local dispensary is safe and meets quality control standards. BLOCKStrain enhances trust of origin from genome-to-sale as cannabis flows through the supply chain, verifying critical steps in the process such as who is growing the plant, which seed is planted and where did it come from, whether pesticides were used, how much was grown, which tests are used to establish quality and potency, where the product is transported and how, and whether possession limits are meeting regulatory standards.

In summary, BLOCKStrain has developed the most comprehensive, secure and community-driven cannabis genetics archival platform for cannabis breeders and growers, large and small, to protect and release their varieties into the public domain, all while compensating and rewarding them for their contributions.

BLOCKStrain Technology Corp. (BKKSF), closed the day's trading session at $0.2479, off by 8.19%, on 134,065 volume with 21 trades. The average volume for the last 3 months is 109,844 and the stock's 52-week low/high is $0.11/$0.85.

Recent News


Koios Beverage Corp. (CSE: KBEV) (OTC: KBEVF)

The QualityStocks Daily Newsletter would like to spotlight Koios Beverage Corp. (KBEVF).

Koios Beverage Corp. (CSE:KBEV)(OTC: KBEVF) (the "Company" or "Koios") is pleased to announce that the world's first cannabis infused nootropic beverage is scheduled for release in November.

Koios Beverage Corp. (CSE: KBEV) (OTC: KBEVF) develops and distributes nature-based products that boost brain function, enhance health, and improve productivity. Its core vision is to help a billion people worldwide live more productively through the development of nootropics, which are supplements that improve cognitive abilities.

The company’s flagship product, Koios, is a GMP-certified dietary supplement. Made from natural ingredients and backed by science, Koios is designed to improve focus, memory, mental drive, clarity and energy. The company produces Koios in the following formulations:

  • Powder supplements containing nootropics as well as caffeine and lion’s mane and chaga mushrooms;
  • Vegan-friendly capsules;
  • Canned beverages containing nootropics along with MCT oil to burn fat and increase metabolism.

Not to be mistaken with prescription-only drugs which are at times used for similar effects, nootropics are over-the-counter dietary supplements; some of which, like Koios, contain ingredients that are currently used in the treatment of patients with Alzheimer’s disease. The global field of nootropics is growing rapidly and expected to reach USD $6,059.4 Mn by 2024 with a CAGR of 17.9 percent from 2016 to 2024.

According to media reports, there is believed to be significant and growing use of nootropics among high-achieving students and professionals. The UK’s leading Guardian newspaper found that nootropics are commonly used in Silicon Valley by computer industry professionals who want to “hack” their minds and maximize their productivity without any possible negative effects on the brain.

Koios was born out of the personal struggles of its founder and CEO, Chris Miller, who has ADHD. Miller found that the symptoms of his condition held him back when navigating the competitive modern workplace. Unhappy with the effects of the Adderall he was prescribed, Chris began a search for a natural remedy that would improve his attention and mental capacity.

Speaking of his struggles at this time, Miller says, “Coffee and energy drinks were no longer helping me. Eventually, I was drinking so much caffeine that I was beginning to notice negative and troubling health effects.” He adds, “I believed there had to be a better way. Better technology that the earth was providing that I could implement and not only boost my daily performance but take care of my brain and body long-term.” After years of experiments and with the help of leading scientists, he developed Koios, named after the Greek Titan who represented rational intelligence.

Koios contains the following ingredients, among others:

  • Vitamin B12: Crucial for the function of the nervous system and the synthesis of DNA, B12 also helps in the creation of red blood cells.
  • Vitamin B6: This vitamin is crucial for brain development among children and brain function in adults. B6 is also important in the production of key hormones: serotonin, which regulates mood, norepinephrine, which helps us handle stress, and dopamine.
  • Huperzine A: Developed from the Chinese club moss plant, huperzine A is used on Alzheimer’s patients to boost their memories. It is also used to raise energy levels and alertness and is the subject of medical trials to test its efficacy when combined with other drugs.
  • Bacopa: Also known as brahmi, bacopa is an Indian herb used in Ayurvedic medicine to improve concentration and memory. Modern science has recognized its effectiveness, and it is used to treat symptoms caused by Alzheimer’s disease, ADHD and anxiety.
  • Ciwujia: Sports scientists have been interested in this herb since they heard of how mountain climbers in Tibet use it to boost their performance at high altitudes. Peer-reviewed research has shown that Ciwujia has clear positive effects on endurance.

A full breakdown of Koios’ active ingredients is available on the company website.

Additionally, safety is paramount for Koios, with all its products developed in a high-grade nutraceutical laboratory which is GMP-certified and in compliance with FDA guidelines. Koios only uses high-quality ingredients sourced from the best possible locations in order to deliver a product that is not only safe but also “one of the world’s greatest nootropic blends.”

The company’s products can be found online and in stores, both across the United States and internationally, via a continuously growing distribution network.

Koios CEO Chris Miller is supported by a team with strong credentials in medical supplement start-ups, corporate finance and sales, which includes CFO/Director Anthony Jackson, Director Scott Walters, Director Konstantine Lichtenwald and Vice President of Sales Gina Burrus.

With people seeking a mental edge and cognitive boost, Koios believes that there is an opening in the market for its nature-based, over-the-counter nootropics, especially when current prescription medicines have worrying side effects..

Koios Beverage Corp. (KBEVF), closed the day's trading session at $0.2479, off by 9.49%, on 323,073 volume with 243 trades. The average volume for the last 3 months is 555,231 and the stock's 52-week low/high is $0.001/$0.8142.

Recent News


PreveCeutical Medical Inc. (CSE: PREV) (OTC: PRVCF) (FSE: 18H)

The QualityStocks Daily Newsletter would like to spotlight PreveCeutical Medical Inc. (PRVCF).

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical"), and Asterion Cannabis Inc. ("Asterion") announce that they have entered into a development and joint venture agreement (the "Development Agreement") to form a joint venture ("Joint Venture") to develop a range of medicinal cannabinoid products, including sublingual tablets, transdermal patches, and other jointly evaluated products aimed at treating various ailments, such as chronic pain, inflammation, epilepsy and anxiety disorders.

PreveCeutical Medical Inc. (CSE: PREV) (OTC: PRVCF) (FSE:18H), headquartered in Vancouver, British Columbia, Canada, is a health sciences company dedicated to researching and developing innovative options for preventive and curative therapies utilizing organic and Nature Identical™ products. The company is strategically staking out select positions in the medically acute areas of diabetes and obesity, pain management, neurological disorders and cancer.

PreveCeutical Medical Inc. had its beginnings in 2009 when Stephen Van Deventer, a seasoned businessman and venture capitalist, and Kimberly Van Deventer, a successful entrepreneur, met and formed a business partnership. The duo created Cornerstone Global Partners, a venture capital and business development company, and became involved in numerous ventures including building companies such as Aurora Cannabis Inc. Taking their interest in the health and wellness market further, the pair began researching how nature and science can work together to benefit health-conscious consumers. Coining and trademarking the word “PreveCeutical” – a combination of the words “preventive” and “pharmaceutical” – was a precursor to the company’s formation and incorporation in October 2015.

The company’s first product was developed in the Dominican Republic and is now marketed and distributed worldwide by PreveCeutical. It is a Caribbean Blue Scorpion venom product sold under the trade name CELLB9®. This product is an oral dilute solution infused with select peptides sourced exclusively from the blue scorpion (Rhopalurus princeps) found only in Caribbean nations. The active potentiated ingredients in CELLB9, which have been used in over 40 countries for over a decade, appear to support health at a deep, cellular level. PreveCeutical’s research team is using proprietary chemistry to generate Nature Identical™ peptides derived from natural compounds found in Caribbean Blue Scorpion venom with the goal of eventually treating, regulating and preventing cancer progression. Peptides are also being used to target an array of disease indications including metabolic disorders, pain management, cancers, cardiovascular and infectious diseases.

PreveCeutical is developing the first nose-to-brain delivery system of cannabinoids (CBDs) with a novel process that prepares insoluble drug-containing nano-micelles and successfully incorporating them into a proprietary sol-gels application, essentially creating a targeted drug delivery vehicle. Intended for use via a nasal spray, this unique formulation rapidly gels upon contact with mucosal tissue, which paves the way for direct nose-to-brain delivery. This novel application eliminates first pass metabolism (stomach, intestines, liver), potentially improving bioavailability and delivering extended time release formulations that may alleviate side effects of higher dosage therapeutics. This CBD-based patented formula is projected to be deployed in selected markets with licensed medical marijuana companies within 18 months.

PreveCeutical is working with four leading Australian research centers to develop a curative therapy for diabetes and obesity. This four-year program involves engineering a novel approach that selectively targets the gene that encodes for the protein PTP-1B, which is implicated and over-expressed in both type-2 diabetes and obesity. PreveCeutical’s gene-silencing technology would effectively “turn off” the genetic signal which leads to the over-production of this key protein molecule, bringing it back down to safe, normalized levels, and prevent the body from storing excessive fat. Diabetes kills one person every six seconds, with more than $800 billion spent globally on the disease.

Another exciting joint venture, established with Sports 1 Marketing, will focus on the therapeutic potential in the peptides and proteins connected to the Caribbean Blue Scorpion venom to potentially treat mild brain injury concussions. Developing a therapeutic product geared towards athletes who suffer from concussions could help alleviate suffering experienced by those who are affected by head trauma.

PreveCeutical Medical’s science and research team is led by Dr. Harendra (Harry) Parekh, Ph.D., who is based at the University of Queensland’s (UQ) Pharmacy Australia Centre of Excellence (PACE), and Dr. Makarand Jawadekar, Ph.D., whose 28 years of R&D experience with Pfizer Inc., is applicable in his role as chief science officer. Research collaborators include Dr. Rakesh Veedu, an emerging expert internationally in the field of molecular medicine, and Professor Grant Ramm, who is currently head of a leading medical research institute located in Brisbane, Australia.

PreveCeutical Medical is partnering with leading industry experts and companies in its quest to be a leader in the preventive health sciences sector. Its Research and Development partnership with UniQuest, the main commercialization company for the University of Queensland, provides PreveCeutical with the rights to all intellectual property arising from projects created under the agreement. PreveCeutical Medical Inc.’s management team brings an extensive portfolio of research experience, product development, deep corporate strategy and capital markets leadership to the company’s core.

PreveCeutical Medical Inc. (PRVCF), closed the day's trading session at $0.0858, off by 14.20%, on 1,173,861 volume with 211 trades. The average volume for the last 3 months is 843,047 and the stock's 52-week low/high is $0.002/$0.20.

Recent News


The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

ActionStockPicksAgressive StocksBetting On Wall StreetCannabisNewsWireGot Stocks?Got Stock Tips?Green Car StocksGreen Energy StocksGreen On The StreetHomeRunStocksMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireQualityStocks MediaQStocksQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsStock BeatsStocks To Buy NowTerrificStocksTiny GemsTip.usTouchdownStocksDaily ToutTraderPower

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.